At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
Pneumococcal (vaccine)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assess Lot-to-lot Consistency of 3 Lots (Double Blind Design) of GlaxoSmithKline Biologicals' 10-valent Pneumococcal Vaccine and Evaluate Non-inferiority to Prevenar™ (Single Blind Design) When Administered as 3-dose Primary Immunization Course Before 6 Months of Age
In Brief
A Phase 3 clinical trial evaluating Pneumococcal (vaccine) for Infections, Streptococcal. Completed, across 35 sites in 3 countries.
Detailed Summary
Evaluate lot-to-lot consistency, safety and reactogenicity of 3 doses of GSK Biologicals' 10-valent pneumococcal conjugate vaccine and non-inferiority with respect to Prevenar.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Streptococcal
CountriesFinland, France, Poland
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedMar 2006
Study CompletionJun 2006
TodayJul 2026
First PostedMar 28, 2006
Enrollment StartNov 1, 2005
Study CompletionJun 1, 2006
TodayJul 2, 2026
Posted 20.3 years ago
Interventions
Pneumococcal (vaccine)biological